In a public health development, Ziekenhuis aan de Stroom (ZAS) is inviting parents of newborns to protect their infants against the respiratory syncytial virus (RSV) using monoclonal antibody immunisation. Recent clinical data indicates this preventive care correlates with a 36 percent reduction in hospital admissions for invasive pneumococcal infections among treated infants.
Understanding the Regional Immunisation Rollout and Clinical Impact
Ziekenhuis aan de Stroom (ZAS) initiated an immunisation campaign, inviting parents of four thousand babies to receive RSV protection. This rollout follows a previous season where ZAS recorded a 73 percent drop in RSV-related admissions for infants under six months of age, plunging from 345 down to 95 hospitalisations. Over all age groups, total RSV admissions fell by 46 percent, dropping from 560 to 305.
Prof. dr. Daan Van Brusselen, a pediatric infectious disease specialist at ZAS and the University of Antwerp, noted the profound relief this brought to clinical wards. “Vroeger namen kinderen met RSV op de piek van het RSV-seizoen meer dan de helft van de bedden op onze kinderafdelingen in,” Van Brusselen explained. The intervention gave pediatric wards breathing room during peak winter months while sparing baby’s and their parents from a stresserende ziekenhuisopname.
In Plain English: The Clinical Takeaway
- Monoclonal Antibodies: Proteins given to protect infants against RSV, providing protection without requiring the infant’s own immune system to build a response from scratch.
- Invasive Pneumococcal Infection: A severe bacterial illness where pneumococci bacteria are found in a normally sterile body site such as the bloodstream, potentially causing complicated pneumonia with pus, sepsis (blood poisoning), or meningitis.
- Efficacy Window: After the administration of antibodies, infants are protected against hospitalisation by almost 80 percent for six months, and by 60 percent during the following winter.
Exploring the Mechanism: Why RSV Prevention Lowers Pneumococcal Severity
Beyond curbing respiratory syncytial virus, a French study published in The Lancet Infectious Diseases revealed that infants receiving RSV antibodies experienced 36 percent fewer hospital admissions for invasive pneumococcal infections. Researchers suspect that an RSV infection can create conditions that make it easier for pneumococci to cause severe disease.
According to data in Flanders, invasive pneumococcal infections are less common than RSV, but usually more severe. Since 2025, four children have died from pneumococci in the region, and survivors frequently face a severe developmental delay. By neutralizing RSV, antibodies appear to cut off the pathways that lead to complicated pneumonia, sepsis, or meningitis.
| Metric Indicator | Baseline Period | Post-Immunisation Season | Observed Change |
|---|---|---|---|
| Infants under 6 months admitted with RSV | 345 admissions | 95 admissions | -73 percent |
| Total RSV-related hospital admissions (all ages) | 560 admissions | 305 admissions | -46 percent |
| Invasive pneumococcal hospitalisation reduction | Standard baseline | French cohort study data | -36 percent |
References
- The Lancet Infectious Diseases. (2026). Epidemiological impact of RSV immunisation on invasive pneumococcal disease. The Lancet Infectious Diseases Abstract
- De Specialist. (2026). RSV-antistoffen gelinkt aan minder zware pneumokokkeninfecties bij kinderen.
- Ziekenhuis aan de Stroom (ZAS). (2026). Immunisatiecampagne RSV en opnamecijfers.
Disclaimer: This article is for informational and educational purposes only and should not be construed as professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.
